[{"from": "human", "value": "What can you tell me about this molecule? [C][C@][C][C][C@@H1][Branch2][Ring2][#Branch1][C][C][Ring1][=Branch1][=C][C][C@@H1][C@@H1][Ring1][#Branch2][C][C][C@][Branch2][Ring1][=Branch1][C@H1][Ring1][=Branch1][C][C][=C][Ring1][Branch1][N][C][=N][C][=C][C][=C][C][=C][Ring1][=Branch1][Ring1][=Branch2][C][O]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling. Localized to the endoplasmic reticulum (ER), the cytochrome P450 enzyme CYP17 (P450C17 or CYP17A1) exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens."}]